Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Marie Skłodowska-Curie Action · Running

SUNSET Targeting cancer with multi-engineered selenium nanoparticles (SeNPs): Development of a biocompatible nanocomposite for targeted gene therapy in BRAF-mutated resistant melanoma.

Coordinator
Academisch Ziekenhuis Groningen, Netherlands
Runs
1 June 2023 to 31 May 2025
Status
Running
EU funding
€188k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101103122

What the project is doing

In the project's own words, from its summary on CORDIS.

Nanotechnology has grown at an exponential rate in the last decade, finding a large application in the biomedical field. Nanoparticles are emerging as effective drug delivery tools, since they overcome most limitations of free therapeutics - while offering a series of physical/chemical advantages. Among engineered nanomaterials, selenium nanoparticles (SeNPs) have shown a growing potential as a therapeutic platform since they offer both the properties of selenium (Se) and the ones of a nanoscale system.

SUNSET project aims is to design and develop a hydrogel-based nanocomposite containing multi-functionalised SeNPs, to use as an effective nanoplatform for cancer gene therapy. The designed system will be evaluated in resistant melanoma, specifically BRAF mutated lesions, which represent 66% of the cancer cases and are those that show resistance to currently available therapies, causing most cancer deaths. Here, the synthesis of SeNPs is followed by surface functionalisation with a specific small interfering RNA (siRNA) and their embedding in the polymeric phase.

All the materials will be synthesised through green chemistry routes, to guarantee a low environmental impact of the procedure and its scalability and reproducibility. The anticancer activity of the nanocomposite will be evaluated both in vitro and in vivo. Overall, the combination of RNAi technology, nanomedicine and biocompatible materials – selenium and natural hydrogels – will be useful to gain a more efficient therapy, overcoming the main current challenges in the care of resistant melanomas.

Moreover, the simplicity of the fabrication and the possibility to scale up the procedure, make the proposed system possibly attractive for clinical applications, promoting European Scientific Excellence. Lastly, I will have the possibility to start new cross-disciplinary collaborations that will pave the way for my future research career.

Topics

Who is involved

OrganisationCityCountryRole
Academisch Ziekenhuis GroningenGroningenNetherlandsCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI